Acurx Pharmaceuticals LLC Total Liabilities
Acurx Pharmaceuticals LLC total liabilities. Based on the latest financial reports, Acurx Pharmaceuticals LLC (ACXP) has total liabilities worth $2.83 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See ACXP defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Acurx Pharmaceuticals LLC (2019–2025)
Total liabilities of Acurx Pharmaceuticals LLC from 2019 to 2025. This chart illustrates how Acurx Pharmaceuticals LLC's total liabilities have evolved over time, based on quarterly financial data.
Acurx Pharmaceuticals LLC Competitors by Total Liabilities
The table below lists competitors of Acurx Pharmaceuticals LLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Erika Carmel-Tech Ltd
TA:ERKA
|
Israel | ILA21.86 Million |
|
Zonte Metals Inc
V:ZON
|
Canada | CA$1.72 Million |
|
Newton Golf Company
NASDAQ:NWTG
|
USA | $5.99 Million |
|
Sawang Export Public Company Limited
BK:SAWANG
|
Thailand | ฿37.47 Million |
|
Innity Corporation Bhd
KLSE:0147
|
Malaysia | RM39.63 Million |
|
NanoVibronix Inc
NASDAQ:NAOV
|
USA | $11.92 Million |
|
Pure Biologics Spólka Akcyjna
WAR:PUR
|
Poland | zł20.72 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Acurx Pharmaceuticals LLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Acurx Pharmaceuticals LLC (ACXP) total assets.
Liquidity & Leverage Metrics
Acurx Pharmaceuticals LLC Total Liabilities Ratios Explained
Acurx Pharmaceuticals LLC total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.88 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.35 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Acurx Pharmaceuticals LLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Acurx Pharmaceuticals LLC (2019–2025)
The table below shows the annual total liabilities of Acurx Pharmaceuticals LLC from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $2.42 Million | -25.35% |
| 2024-12-31 | $3.24 Million | +6.59% |
| 2023-12-31 | $3.04 Million | +47.57% |
| 2022-12-31 | $2.06 Million | +144.30% |
| 2021-12-31 | $843.91K | +61.53% |
| 2020-12-31 | $522.43K | -69.48% |
| 2019-12-31 | $1.71 Million | -- |
About Acurx Pharmaceuticals LLC
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potenti… Read more